Stock Spotlights Archives - Page 9 of 19

FridayJan 20, 2023 12:25 pm

TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Reaches Pivotal Milestone to Advance ADI (TM) Technology

Aditxt (NASDAQ: ADTX) recently announced the formation of a U.S.-based wholly owned subsidiary, Adimune Inc., and appointed Joachim-Friedrich Kapp, MD, Ph.D, a 30-year veteran of the pharmaceutical industry, as its chairman and CEO. “Dr. Kapp will be tasked with leading and developing the ADI(TM) immune modulation technology and ADI(TM)-100, Aditxt’s unique and potent antigen-specific immunotherapeutic technology drug candidate, toward clinical trials… Short for Apoptotic DNA Immunotherapy(TM), ADI(TM) is a nucleic acid-based technology platform that utilizes a novel antigen-specific approach to induce immune tolerance by mimicking the way the body naturally induces tolerance to its own tissues. The technology, the company…

WednesdayJan 18, 2023 12:25 pm

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) Collaborates to Further Unlock Potential of Its Lidar Technology Across Robotics Applications

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, recently announced that it would be further broadening its technological reach by collaborating with Exwayz to develop novel lidar-based perception solutions for mobile robotics applications. “Exwayz is a developer of plug-and-play perception software designed to enable lidar-based 3D mapping, localization, and re-localization as well as object detection and classification… The venture’s lidar-based solution will provide high-precision 3D data, which can help robotic systems navigate safely and autonomously while enabling operators to easily track their locations, gaining critical insights into how a space is being utilized,” a recent…

ThursdayJan 12, 2023 2:29 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves Closer Toward Broad Applications of Patented DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX) in 2022 achieved crucial milestones centered around its patented DehydraTECH(TM) drug delivery technology. “For Lexaria, the end goal does not only lie in uncovering DehydraTECH’s ability to improve the bioavailability of various APIs. Instead, the company is keen on establishing whether DehydraTECH can be applied broadly within the pharmaceutical industry. And calendar 2022 has brought Lexaria closer to realizing this goal, with the company initiating a slew of research programs, many of which it has already completed. Moreover, its intellectual property (‘IP’) portfolio received additional patent protection in different jurisdictions around the world. Lexaria also…

WednesdayJan 11, 2023 12:03 pm

TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Dedicated to New Era of Precision Medicine

Aditxt (NASDAQ: ADTX), a biotech innovation company, is developing and commercializing technologies with a focus on monitoring and modulating, mapping and reprogramming the immune system, designing technologies to provide a personalized immune profile. “In late October 2022, Aditxt announced the creation of its Adimune(TM) program. At the same time, Aditxt announced that Adimune initiated the GMP manufacturing of drug candidate ADI(TM)-100 for purposes of initiating human trials. The trial will be performed in autoimmune diseases, with psoriasis as the first indication to be studied. Adimune’s nucleic acid-based technology, ADI(TM), has shown in preclinical studies the ability to restore/induce immune tolerance…

MondayJan 09, 2023 1:10 pm

TinyGemsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Leveraging Colombia, US Facilities to Distinguish Itself Within Highly Competitive Space

Flora Growth Corp. (NASDAQ: FLGC), a cannabis cultivator and global distributor, is a rapidly growing house of brands building customer bases and distribution channels across international lines as it aims to distinguish itself within a highly competitive arena. “Much of Flora Growth’s strength lies in its licensed cultivation, extraction and isolation facility located in northern Colombia’s fertile climate, where an experienced labor force is helping the nation emerge from decades of drug war illicit trade into a recognized and regulated market,” a recent article reads. “From its 247 acres of growing fields, the company’s harvests move into a production pipeline…

MondayJan 09, 2023 12:19 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Poised to Potentially Change History

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical innovator, is enrolling patients in the United States and Europe for its potentially pivotal global clinical trial in humans for its lead drug candidate designed to treat glioblastoma multiforme (“GBM”), a common and one of the most aggressive primary brain cancers. “The drug, Berubicin, is an anthracycline chemotherapy agent that apparently has the unique ability to cross the blood-brain barrier to target tumors directly. The inability of anthracyclines to cross the blood-brain barrier has been identified as a major obstacle in treating aggressive brain tumors such as GBM and creates an opportunity for CNS…

ThursdayJan 05, 2023 1:15 pm

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Secures Stream of Steady Business on Fr8App Platform

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a company specializing in creating and providing supply chain optimization and automation solutions, and Freight App Inc. (“Fr8App”), its wholly owned subsidiary, have always sought to create offerings that contribute to their clients’ success by improving efficiency and profitability. “Designed to help solve shippers’ needs to secure freight capacity over time rather than on a trip-by-trip basis and guarantee carriers a steady stream of revenue, Fr8PrivateFleet matches carriers with the capacity for predetermined amount of load over a stated period with shippers… The advantages of Fr8PrivateFleet persuaded new and existing Fr8App customers to integrate it…

WednesdayJan 04, 2023 1:36 pm

TinyGemsBreaks – Vision Energy Corp.’s (VENG) Pioneering Terminal Set to Accelerate Energy Transition

Vision Energy (OTCQB: VENG) recently entered into a corporation agreement with Linde Engineering to accelerate efforts for the company’s pioneering Green Energy Terminal in the North Sea Port of Vlissingen, the Netherlands. “Linde Engineering, a leading global industrial gases and engineering company with 2021 sales of $31 billion, will deliver preliminary Front-End Engineering and Design (‘FEED’) services to the project including design and engineering of 150,000 cubic meters (‘CBM’) of green ammonia (‘NH3’) storage, truck and barge loading facilities, ship loading and unloading facilities, as well as utilities, infrastructure and buildings… Vision Energy is in the advanced stages of planning…

FridayDec 16, 2022 3:18 pm

TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Expected to Yield Notable Results in Diabetes Study

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs. “Lexaria [recently] announced that the study program DIAB-A22-1 [had begun] on schedule, making it the company’s first-ever study to investigate whether its DehydraTECH-processed cannabidiol (‘CBD’) may potentially have therapeutic utility against diabetes,” a recent article reads. “Lexaria is optimistic that its DehydraTECH-CBD will yield notable results from this study, especially having met primary safety and efficacy objectives from its HYPER-H21-4 clinical study. There is a strong connection between heart disease, hypertension and diabetes, with hypertension proving to…

WednesdayDec 14, 2022 2:14 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Committed to Driving Berubicin Program Forward

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments, recently announced that the first patient in Europe had been enrolled and dosed in France in the company’s ongoing global trial to evaluate Berubicin for the treatment of recurrent glioblastoma multiforme (“GMB”), an aggressive and incurable form of brain cancer. “Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier (based upon pre-clinical and limited clinical data) and is currently being evaluated in the potentially pivotal study evaluating efficacy and safety for GBM treatment. This study is an adaptive,…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Breaks Categories: Stock Spotlights